Tetraphase Pharmaceuticals (TTPH) PT Raised $46 at Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Daniel Brims reiterated a Buy rating and boosted his price target on Tetraphase Pharmaceuticals (NASDAQ: TTPH) to ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE